Genistein-induced G2-M arrest, p21(WAF1) upregulation, and apoptosis in a non-small-cell lung cancer cell line

Nutrition and Cancer

Volumn 31, Issue 3, 1998, Pages 184-191

  Lian, Fangru ^a   Bhuiyan, Mahbubur ^a   Li, Yi Wei ^a   Wall, Nathan ^a   Kraut, Michael ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; DNA; GENISTEIN; INDOLE DERIVATIVE; ISOFLAVONE; PROTEIN P21; ANTINEOPLASTIC AGENT; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; ENZYME INHIBITOR;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL GROWTH; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; METAPHASE; MITOSIS INHIBITION; CELL CULTURE; DRUG EFFECT; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; METABOLISM; UPREGULATION;

ANTICARCINOGENIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME INHIBITORS; FLOW CYTOMETRY; G2 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENISTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0031595611     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635589809514701     Document Type: Article

References (32)

1. Blair, SL, Heerdt, P, Sachar, S, Abolhoda, A, Hochwald, S, et al.: Glutathione metabolism in patients with non-small cell lung cancers. Cancer Res 57, 152-155, 1997.
2. Bastin, KT, and Curley, R: Non-small-cell lung carcinoma: current and future therapeutic management. Drugs 49, 362-375, 1995.
3. Barkley, JE, and Green, M: Bronchioloalveolar carcinoma. J Clin Oncol 14, 2377-2386, 1996.
4. 2-M. Cancer Res 53, 1328-1331, 1997.
5. Spinozzi, F, Pagliacci, MC, Migliorati, G, Moraca, R, Grignani, F, et al.: The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat T-leukemia cells. Leukemia Res 198, 431-439, 1994.
6. Constantinou, A, Kiguchi, K, and Iuberman, E: Induction of differentiation and strand breakage in human HL-60 and K-562 leukemia cells by genistein. Cancer Res 50, 2618-2624, 1990.
7. Peterson, G: Evaluation of the biochemical targets of genistein in tumor cells. J Nutr 125, 784s-789s, 1995.
8. Akiyama, T, Ishida, J, Nakagawa, S, Ogawara, H, Watanabe, S, et al.: Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262, 5592-5595, 1987.
9. Feller, SM, and Wong, TW: Identification and characterization of a cytosolic protein tyrosine kinase of HeLa cells. Biochemistry 31, 3044-3051, 1992.
10. Burke, TR: Protein-tyrosine kinase inhibitors. Drug Future 17, 119-131, 1992.
11. Hollenberg, MD: Tyrosine kinase-mediated signal transduction pathways and actions of polypeptide growth factors and G-protein-coupled agonists in smooth muscle. Mol Cell Biochem 149, 77-85, 1995.
12. Simon, HI, Yousefi, S, and Blaser, K: Tyrosine phosphorylation regulates activation and inhibition of apoptosis in human eosinophils and neutrophils. Int Arch Allergy Appl Immunol 107, 338-339, 1995.
13. Kyle, E, Neckers, L, Takimoto, C, Curt, G, and Gergan, R: Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Mol Pharmacol 51, 193-200, 1997.
14. Barlogie, B, Barber, MN, and Schumann, J: Flow cytometry in clinical cancer research. Cancer Res 43, 3977-3982, 1983.
15. Philpott, NJ, Turner, AJ, Scopes, J, Westby, M, Marsh, JC, et al.: The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood 87, 2244-2251, 1996.
16. 2-M arrest. J Biol Chem 271, 29556-29560, 1996.
17. Hunakova, L, Sedlak, J, Klobusicka, M, Duraj, J, and Chorvath, B: Tyrosine kinase inhibitor-induced differentiation of K-562 cells: alterations of cell cycle and cell surface phenotype. Cancer Lett 81, 81-87, 1994.
18. 2 by X-irradiation. Int J Radiat Biol 67, 347-358, 1995.
19. Roberts, JM, Koff, A, Polyak, K, Firpo, E, Collins, S, et al.: Cyclins, cdks, and cyclin kinase inhibitors. Cold Spring Harbor Symp Quant Biol 59, 31-38, 1994.
20. Sherr, CJ: Cancer cell cycles. Science 274, 1672-1677, 1994.
21. Earnshaw, WC, and Heck, M: Localization of topoisomerase II in mitotic chromosomes. J Cell Biol 100, 1706-1715, 1985.
22. Heck, M, and Earnshaw, WC: Topoisomerase II: a specific marker for cell proliferation. J Cell Biol 103, 2569-2581, 1986.
23. Estey, EH, Silberman, L, Beran, M, Andersson, BS, and Zwelling, LA: The interaction between nuclear topoisomerase II activity from human leukemia cells, exogenous DNA, and 4′-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) or 4-(4,6-O-ethylidene-β-D-glucopyranoside) (VP-16) indicates the sensitivity of the cells to the drugs. Biochem Biophys Res Commun 144, 787-793, 1987.
24. 2 phase arrest by different antitumor agents. Eur J Cancer 14, 741-745, 1978.
25. 2 phase of the cell cycle. Cancer Res 35, 99-105, 1975.
26. 1 phase progression: cycling on cue. Cell 79, 551-555, 1994.
27. Xiong, Y, Hannon, GJ, Zhang, H, Casso, D, Kobayashi, R, et al.: p21 is a universal inhibitor of cyclin kinases. Nature 366, 701-704, 1993.
28. Kerr, JF, Winterford, CM, and Harmon, BV: Apoptosis: its significance in cancer and cancer therapy. Cancer 73, 2013-2026, 1993.
29. Markovitz, J, Linassier, C, Fossi, P, Couprie, J, Pierre, J, et al.: Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res 119, 5111-5117, 1989.
30. Yamashita, Y, Kawada, S, and Nakano, H: Induction of mammalian topoisomerase II-dependent DNA cleavage by nonintercalative flavonoids, genistein and phorobol. Biochem Pharmacol 39, 737-744, 1990.
31. Adlercreutz, H, Markkanen, H, and Watanabe, S: Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 342, 1209-1210, 1993.
32. Barnes, S: Effects of genistein on in vivo models of cancer. J Nutr 125, 777s-783s, 1995.